A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of Evolocumab (AMG145) on LDL-C in Subjects With Severe Familial Hypercholesterolemia.

Trial Profile

A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of Evolocumab (AMG145) on LDL-C in Subjects With Severe Familial Hypercholesterolemia.

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Evolocumab (Primary)
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Adverse reactions; Registrational
  • Acronyms PROFICIO; TAUSSIG
  • Sponsors Amgen
  • Most Recent Events

    • 30 Aug 2017 Results (n=14) presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 21 Aug 2017 According to an Amgen media release, data feom this trial will be presented at the European Society of Cardiology (ESC) Congress 2017.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top